-
12 Stocks Moving In Friday's Pre-Market Session
Friday, September 9, 2016 - 8:29am | 465Gainers Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares rose 18 percent to $18.05 in pre-market trading as the company reported first successful Phase 3 trial of an oral anti-diabetic for Type 1 diabetes. Finisar Corporation (NASDAQ: FNSR) shares rose 16.2 percent to $27.00 in pre-...
-
18 Biggest Mid-Day Gainers For Wednesday
Wednesday, September 7, 2016 - 12:58pm | 636Retrophin Inc (NASDAQ: RTRX) shares climbed 40.8 percent to $22.97 as the company disclosed that its Phase 2 DUET study of sparsentan achieved primary efficacy endpoint. Cogentix Medical Inc (NASDAQ: CGNT) shares climbed 39.1 percent to $1.67 after the company disclosed that it has...
-
Benzinga's Top Upgrades
Wednesday, September 7, 2016 - 8:57am | 306Analysts at CIBC upgraded Spectra Energy Corp. (NYSE: SE) from Sector Performer to Outperformer. Spectra Energy shares declined 1.10 percent to $40.55 in pre-market trading. Deutsche Bank upgraded Ligand Pharmaceuticals Inc. (NASDAQ: LGND) from Sell to Hold. Ligand shares rose 0....
-
20 Biggest Mid-Day Losers For Wednesday
Wednesday, August 10, 2016 - 1:06pm | 717Myriad Genetics, Inc. (NASDAQ: MYGN) shares declined 32.1 percent to $20.00 after the company posted weaker-than-expected Q4 results and issued a downbeat guidance. SunPower Corporation (NASDAQ: SPWR) shares declined 30.2 percent to $10.32 after the company posted a loss for its...
-
Benzinga's Top Initiations
Wednesday, June 29, 2016 - 9:30am | 390Bernstein initiated coverage on Amgen, Inc. (NASDAQ: AMGN) with a Market Perform rating. Amgen shares rose 0.97 percent to $149.86 in pre-market trading. BMO Capital initiated coverage on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Market Perform rating. Valeant shares...
-
Neurocrine Reports Added NBI-98854 Data Will Be Presented at APA Meeting
Friday, May 6, 2016 - 8:32am | 309Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that four abstracts representing additional data from both the Kinect 3 and Kinect 2 tardive dyskinesia clinical trials of valbenazine will be presented at the American Psychiatric Association Annual Meeting in May. The four posters will...
-
Earnings Scheduled For March 22, 2016
Tuesday, March 22, 2016 - 4:04am | 449G-III Apparel Group, Ltd. (NASDAQ: GIII) is estimated to report its quarterly earnings at $0.42 per share on revenue of $568.61 million. Nike Inc (NYSE: NKE) is projected to post its quarterly earnings at $0.49 per share on revenue of $8.20 billion. Red Hat Inc (NYSE: RHT) is estimated to post...
-
Benzinga's Top Initiations
Thursday, March 3, 2016 - 11:01am | 386Analysts at SunTrust Robinson Humphrey initiated coverage on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with a Neutral rating. The target price for Regeneron Pharmaceuticals is set to $450. Regeneron Pharmaceuticals shares closed at $407.81 on Wednesday. KeyBanc initiated coverage on Saia Inc...
-
Benzinga's Top Initiations
Tuesday, February 9, 2016 - 10:53am | 366Analysts at Maxim Group initiated coverage of Cheesecake Factory Inc (NASDAQ: CAKE) with a Buy rating. The target price for Cheesecake Factory is set to $57. Cheesecake Factory shares closed at $47.27 on Monday. UBS initiated coverage on Depomed Inc (NASDAQ: DEPO) with a Buy rating. The target...
-
Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
Wednesday, December 16, 2015 - 5:06pm | 374Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has successfully completed the Phase Ib T-Force study of NBI-98854 (valbenazine), a once-daily, highly selective, small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor. The T-Force Study evaluated several doses of...
-
Telotristat Etiprate Achieves Positive Top-Line Results In Second Phase 3 Clinical Trial, Met Primary Endpoint
Tuesday, December 1, 2015 - 9:08am | 1048Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its...
-
La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
Monday, November 30, 2015 - 9:02am | 235La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced the issuance of a Notice of Allowance from the United...
-
Morning Market Gainers
Friday, November 6, 2015 - 10:43am | 404ZS Pharma Inc (NASDAQ: ZSPH) shares jumped 40.69 percent to $89.07 after the company agreed to be acquired by AstraZeneca plc (ADR) (NYSE: AZN) for $2.7 billion. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares surged 34.06 percent to $14.13. Lexicon Pharma reported a Q3 loss of $0.34 per...
-
Sanofi, Lexicon to Collaborate on Sotagliflozin, a Potential Diabetes Treatment
Friday, November 6, 2015 - 5:21am | 211Sanofi (NYSE: SNY) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT...
-
Cancer Patients Treated With Lexicon's Telotristat Etiprate Report Improved Function And Well-Being
Monday, October 19, 2015 - 7:03am | 255Lexicon Pharmaceuticals, Inc.'s (Nasdaq: LXRX) telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data...